PARP Inhibitors in Ovarian Cancer: The Route to “Ithaca”

PARP Inhibitors in Ovarian Cancer: The Route to “Ithaca”

Poly (ADP-ribose) polymerase (PARP) inhibitors are a novel class of therapeutic agents that target tumors with deficiencies in the homologous recombination DNA repair pathway. Genomic instability characterizes high-grade serous ovarian cancer (HGSOC), with one half of all tumors displaying defects i...

Full description

Bibliographic Details
Main Authors:	Stergios Boussios, Afroditi Karathanasi, Deirdre Cooke, Cherie Neille, Agne Sadauskaite, Michele Moschetta, Nikolaos Zakynthinakis-Kyriakou, Nicholas Pavlidis
Format:	Article
Language:	English
Published:	MDPI AG 2019-05-01
Series:	Diagnostics
Subjects:	ovarian cancer BRCA PARP inhibitors homologous recombination companion diagnostic toxic effects resistance mechanism
Online Access:	https://www.mdpi.com/2075-4418/9/2/55

Similar Items

Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review
by: Stergios Boussios, et al.
Published: (2019-08-01)

Efficacy of PARP Inhibitors in the Treatment of Ovarian Cancer: A Literature-Based Review
by: Vikas Goswami, et al.
Published: (2019-01-01)

Wise Management of Ovarian Cancer: On the Cutting Edge
by: Stergios Boussios, et al.
Published: (2020-05-01)

PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies
by: Elizabeth K. Lee, et al.
Published: (2020-07-01)

Efficacy and Prognostic Factors for PARP Inhibitors in Patients With Ovarian Cancer
by: Xuan-zhang Huang, et al.
Published: (2020-06-01)

Integration of PARP-inhibitors in ovarian cancer therapy
by: Antonella Pietragalla, et al.
Published: (2020-06-01)

Successes and challenges of PARP inhibitors in cancer therapy
by: Tiffany K Ricks, et al.
Published: (2015-10-01)

Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer
by: Colombo I, et al.
Published: (2018-03-01)

The evolving role of PARP inhibitors in advanced ovarian cancer
by: Levva Sofia, et al.
Published: (2021-08-01)

PARP Inhibitors Display Differential Efficacy in Models of <i>BRCA</i> Mutant High-Grade Serous Ovarian Cancer
by: Kristie-Ann Dickson, et al.
Published: (2021-08-01)

Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management
by: Renata Rodrigues da Cunha Colombo Bonadio, et al.
Published: (2018-08-01)

PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?
by: Elisena Franzese, et al.
Published: (2020-06-01)

Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer
by: Michelle McMullen, et al.
Published: (2020-06-01)

PARP Inhibitors in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Meta-Analysis of Randomized Clinical Trials
by: Yizi Wang, et al.
Published: (2020-08-01)

Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy
by: Lorusso D, et al.
Published: (2018-05-01)

Preclinical Studies on the Effect of Rucaparib in Ovarian Cancer: Impact of BRCA2 Status
by: Sayeh Saravi, et al.
Published: (2021-09-01)

A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
by: Marta Castroviejo‐Bermejo, et al.
Published: (2018-12-01)

PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications
by: Heng Zhu, et al.
Published: (2020-03-01)

Poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA1/2 cancer therapy
by: Katarzyna Kluzek, et al.
Published: (2012-06-01)

Reviewing the characteristics of BRCA and PALB2-related cancers in the precision medicine era
by: Gabriel S. Macedo, et al.
Published: (2019-04-01)

The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells
by: Silvana eDe Lorenzo, et al.
Published: (2013-09-01)

Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer
by: Dockery LE, et al.
Published: (2017-06-01)

PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date
by: Nizialek E, et al.
Published: (2020-09-01)

<i>BRCA</i> Genetic Test and Risk-Reducing Salpingo-Oophorectomy for Hereditary Breast and Ovarian Cancer: State-of-the-Art
by: Masayuki Sekine, et al.
Published: (2021-05-01)

Exploiting the Prevalence of Homologous Recombination Deficiencies in High-Grade Serous Ovarian Cancer
by: Sara Bouberhan, et al.
Published: (2020-05-01)

Translational Research Opportunities Regarding Homologous Recombination in Ovarian Cancer
by: Margarita Romeo, et al.
Published: (2018-10-01)

Tailoring Ovarian Cancer Treatment: Implications of <i>BRCA1/2</i> Mutations
by: Ainhoa Madariaga, et al.
Published: (2019-03-01)

Loss of CENP-I Impairs Homologous Recombination and Sensitizes Cells to PARP1 Inhibition
by: Tuyen T. Dang, et al.
Published: (2021-06-01)

PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting
by: Karolina N. Dziadkowiec, et al.
Published: (2017-02-01)

Recent Advances in Enhancing the Therapeutic Index of PARP Inhibitors in Breast Cancer
by: Camille Franchet, et al.
Published: (2021-08-01)

Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer
by: Jiang X, et al.
Published: (2019-05-01)

Prostate cancer and PARP inhibitors: progress and challenges
by: Diego Teyssonneau, et al.
Published: (2021-03-01)

Resistance to PARP-inhibitors in Cancer Therapy
by: Alicia eMontoni, et al.
Published: (2013-02-01)

Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors
by: Isabella Faraoni, et al.
Published: (2018-12-01)

PARP Inhibitors as a Novel Treatment Strategy for Patients with BRCA-Mutated Metastatic Breast Cancer
by: Katarzyna Rygiel
Published: (2019-11-01)

Molecular determinants of sensitivity to poly(ADP-ribose) polymerase inhibitors in epithelial ovarian cancer
by: O'Connor, Kevin William
Published: (2016)

PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response
by: Chiho Kim, et al.
Published: (2020-08-01)

PARP Inhibitors in Melanoma—An Expanding Therapeutic Option?
by: Wei Yen Chan, et al.
Published: (2021-09-01)

Clinical Implications of DNA Repair Defects in High-Grade Serous Ovarian Carcinomas
by: Michela Camilla Milanesio, et al.
Published: (2020-05-01)

PARP inhibitors combined with ionizing radiation induce different effects in melanoma cells and healthy fibroblasts
by: Verena Weigert, et al.
Published: (2020-08-01)

Cannot write session to /tmp/vufind_sessions/sess_1b4n7kt1asmrte29bnv6vun7ga